140 related articles for article (PubMed ID: 22749038)
21. Duplication of paternal IGF2 or loss of maternal IGF2 imprinting occurs in half of Wilms tumors with various structural WT1 abnormalities.
Haruta M; Arai Y; Sugawara W; Watanabe N; Honda S; Ohshima J; Soejima H; Nakadate H; Okita H; Hata J; Fukuzawa M; Kaneko Y
Genes Chromosomes Cancer; 2008 Aug; 47(8):712-27. PubMed ID: 18464243
[TBL] [Abstract][Full Text] [Related]
22. Wilms tumour histology is determined by distinct types of precursor lesions and not epigenetic changes.
Fukuzawa R; Anaka MR; Heathcott RW; McNoe LA; Morison IM; Perlman EJ; Reeve AE
J Pathol; 2008 Aug; 215(4):377-87. PubMed ID: 18484682
[TBL] [Abstract][Full Text] [Related]
23. SIX2 and CITED1, markers of nephronic progenitor self-renewal, remain active in primitive elements of Wilms' tumor.
Murphy AJ; Pierce J; de Caestecker C; Taylor C; Anderson JR; Perantoni AO; de Caestecker MP; Lovvorn HN
J Pediatr Surg; 2012 Jun; 47(6):1239-49. PubMed ID: 22703800
[TBL] [Abstract][Full Text] [Related]
24. Identification of differential methylation of the WT1 antisense regulatory region and relaxation of imprinting in Wilms' tumor.
Malik K; Salpekar A; Hancock A; Moorwood K; Jackson S; Charles A; Brown KW
Cancer Res; 2000 May; 60(9):2356-60. PubMed ID: 10811108
[TBL] [Abstract][Full Text] [Related]
25. In silico regulatory analysis for exploring human disease progression.
Holloway DT; Kon M; DeLisi C
Biol Direct; 2008 Jun; 3():24. PubMed ID: 18564415
[TBL] [Abstract][Full Text] [Related]
26. Increased expression of the insulin-like growth factor-II gene in Wilms' tumor is not dependent on loss of genomic imprinting or loss of heterozygosity.
Wang WH; Duan JX; Vu TH; Hoffman AR
J Biol Chem; 1996 Nov; 271(44):27863-70. PubMed ID: 8910385
[TBL] [Abstract][Full Text] [Related]
27. Microdissecting the genetic events in nephrogenic rests and Wilms' tumor development.
Charles AK; Brown KW; Berry PJ
Am J Pathol; 1998 Sep; 153(3):991-1000. PubMed ID: 9736048
[TBL] [Abstract][Full Text] [Related]
28. Significant reduction of WT1 gene expression, possibly due to epigenetic alteration in Wilms' tumor.
Satoh Y; Nakagawachi T; Nakadate H; Kaneko Y; Masaki Z; Mukai T; Soejima H
J Biochem; 2003 Mar; 133(3):303-8. PubMed ID: 12761165
[TBL] [Abstract][Full Text] [Related]
29. Sequential WT1 and CTNNB1 mutations and alterations of beta-catenin localisation in intralobar nephrogenic rests and associated Wilms tumours: two case studies.
Fukuzawa R; Heathcott RW; More HE; Reeve AE
J Clin Pathol; 2007 Sep; 60(9):1013-6. PubMed ID: 17172473
[TBL] [Abstract][Full Text] [Related]
30. Abnormal RNA expression of 11p15 imprinted genes and kidney developmental genes in Wilms' tumor.
Schwienbacher C; Angioni A; Scelfo R; Veronese A; Calin GA; Massazza G; Hatada I; Barbanti-Brodano G; Negrini M
Cancer Res; 2000 Mar; 60(6):1521-5. PubMed ID: 10749116
[TBL] [Abstract][Full Text] [Related]
31. Epigenetic alteration at the DLK1-GTL2 imprinted domain in human neoplasia: analysis of neuroblastoma, phaeochromocytoma and Wilms' tumour.
Astuti D; Latif F; Wagner K; Gentle D; Cooper WN; Catchpoole D; Grundy R; Ferguson-Smith AC; Maher ER
Br J Cancer; 2005 Apr; 92(8):1574-80. PubMed ID: 15798773
[TBL] [Abstract][Full Text] [Related]
32. Loss of heterozygosity at 7p in Wilms' tumour development.
Powlesland RM; Charles AK; Malik KT; Reynolds PA; Pires S; Boavida M; Brown KW
Br J Cancer; 2000 Jan; 82(2):323-9. PubMed ID: 10646884
[TBL] [Abstract][Full Text] [Related]
33. β-Catenin and K-RAS synergize to form primitive renal epithelial tumors with features of epithelial Wilms' tumors.
Clark PE; Polosukhina D; Love H; Correa H; Coffin C; Perlman EJ; de Caestecker M; Moses HL; Zent R
Am J Pathol; 2011 Dec; 179(6):3045-55. PubMed ID: 21983638
[TBL] [Abstract][Full Text] [Related]
34. WNT/beta-catenin pathway activation in Wilms tumors: a unifying mechanism with multiple entries?
Corbin M; de Reyniès A; Rickman DS; Berrebi D; Boccon-Gibod L; Cohen-Gogo S; Fabre M; Jaubert F; Faussillon M; Yilmaz F; Sarnacki S; Landman-Parker J; Patte C; Schleiermacher G; Antignac C; Jeanpierre C
Genes Chromosomes Cancer; 2009 Sep; 48(9):816-27. PubMed ID: 19530245
[TBL] [Abstract][Full Text] [Related]
35. Wilms' tumours: about tumour suppressor genes, an oncogene and a chameleon gene.
Huff V
Nat Rev Cancer; 2011 Feb; 11(2):111-21. PubMed ID: 21248786
[TBL] [Abstract][Full Text] [Related]
36. Berberine inhibits Wilms' tumor cell progression through upregulation of Wilms' tumor gene on the X chromosome.
Liu Y; Liu S
Mol Med Rep; 2013 Nov; 8(5):1537-41. PubMed ID: 24002362
[TBL] [Abstract][Full Text] [Related]
37. Wilms tumor cells with WT1 mutations have characteristic features of mesenchymal stem cells and express molecular markers of paraxial mesoderm.
Royer-Pokora B; Busch M; Beier M; Duhme C; de Torres C; Mora J; Brandt A; Royer HD
Hum Mol Genet; 2010 May; 19(9):1651-68. PubMed ID: 20106868
[TBL] [Abstract][Full Text] [Related]
38. [Wilms' tumors and malformation complexes].
Hata J; Fukuzawa R; Takata A; Kikuchi H
Nihon Rinsho; 2000 Jul; 58(7):1419-25. PubMed ID: 10921316
[TBL] [Abstract][Full Text] [Related]
39. Classification of a frameshift/extended and a stop mutation in WT1 as gain-of-function mutations that activate cell cycle genes and promote Wilms tumour cell proliferation.
Busch M; Schwindt H; Brandt A; Beier M; Görldt N; Romaniuk P; Toska E; Roberts S; Royer HD; Royer-Pokora B
Hum Mol Genet; 2014 Aug; 23(15):3958-74. PubMed ID: 24619359
[TBL] [Abstract][Full Text] [Related]
40. Distinctive properties of an anaplastic Wilms' tumor and its associated epithelial cell line.
Hazen-Martin DJ; Re GG; Garvin AJ; Sens DA
Am J Pathol; 1994 May; 144(5):1023-34. PubMed ID: 8178926
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
